GSK (NYSE:GSK) Upgraded to “Strong-Buy” at StockNews.com

GSK (NYSE:GSK) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Monday.

GSK has been the topic of a number of other reports. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $33.08 on Monday. The stock has a market capitalization of $68.56 billion, a PE ratio of 21.48, a PEG ratio of 1.52 and a beta of 0.63. GSK has a one year low of $32.83 and a one year high of $45.92. The business’s 50 day simple moving average is $34.38 and its 200 day simple moving average is $38.17. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GSK. Ashton Thomas Private Wealth LLC bought a new stake in shares of GSK in the 2nd quarter valued at about $37,000. American Century Companies Inc. boosted its stake in GSK by 42.2% during the 2nd quarter. American Century Companies Inc. now owns 544,079 shares of the pharmaceutical company’s stock worth $20,947,000 after purchasing an additional 161,448 shares during the last quarter. BOKF NA boosted its stake in GSK by 20.8% during the 2nd quarter. BOKF NA now owns 10,389 shares of the pharmaceutical company’s stock worth $400,000 after purchasing an additional 1,787 shares during the last quarter. Thoroughbred Financial Services LLC boosted its stake in GSK by 6.6% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 6,908 shares of the pharmaceutical company’s stock worth $265,000 after purchasing an additional 428 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of GSK by 11.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 105,927 shares of the pharmaceutical company’s stock valued at $4,078,000 after acquiring an additional 10,942 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.